Key Highlights

  • PermeaDerm achieved a statistically significant 70% cost advantage over cadaveric allograft based on treatment cost per 1% total body surface area.
  • Mean treatment cost was $148.70 per 1% TBSA treated with PermeaDerm versus $497.10 for allograft.
  • Preparation time was reduced by 95.7%, while clinical outcomes including graft take and wound healing were reported as comparable.
  • The randomized controlled study enrolled 40 patients across 11 U.S. burn centres, with no adverse events attributed to PermeaDerm.

AVITA Medical (NASDAQ:RCEL, ASX:AVH) shares have surged 109.16% in the past month, with the stock last changing hands at AUD 2.74. The move follows the release of positive results from the PermeaDerm-I multicentre randomized controlled study.

Study Results Behind the Move

The trial's primary endpoint compared treatment cost per percentage of total body surface area (TBSA) treated. PermeaDerm recorded a mean cost of $148.70 per 1% TBSA, against $497.10 for allograft — a saving of roughly $348 per percentage point and a 70% lower product cost, statistically significant at p<0.001.

PermeaDerm's off-the-shelf format cut preparation time by 95.7% versus allograft, avoiding tissue tracking, thawing and meshing. Application time in theatre was comparable between groups, and the product's transparent structure lets clinicians view the wound bed without removing it.

Clinical Outcomes

The study enrolled 40 patients at 11 U.S. burn centres, with wounds up to 30% TBSA. About 94% of PermeaDerm patients achieved at least 95% graft take one week after autografting. At eight weeks, all patients in both groups reached at least 95% wound healing, with no adverse events attributed to PermeaDerm.

Is AVH Worth Watching?

The results add fresh clinical and economic data to AVITA's acute wound care portfolio, which also includes RECELL and Cohealyx. The company holds exclusive U.S. rights to manufacture and distribute PermeaDerm. No revenue, NPAT or Dividend changes were reported alongside the study.